HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer

HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer

First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer

HanchorBio receives FDA orphan drug status for gastric cancer therapy

TAIPEI, SHANGHAI and SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to HCB101 for the treatment of gastric cancer. The designation covers gastric cancer broadly, including advanced gastric ad…

FDA Grants Orphan Drug Designation to HCB101 in HER2+/– Gastric Cancer

HCB101 in combination with HER2-targeted therapy or ramucirumab plus paclitaxel achieved positive responses among patients with first- and second-line gastric cancer.